MilliporeSigma
All Photos(1)

Y0001046

Sevoflurane

European Pharmacopoeia (EP) Reference Standard

Synonym(s):
1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane
Empirical Formula (Hill Notation):
C4H3F7O
CAS Number:
Molecular Weight:
200.05
NACRES:
NA.24

grade

pharmaceutical primary standard

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

InChI

1S/C4H3F7O/c5-1-12-2(3(6,7)8)4(9,10)11/h2H,1H2

InChI key

DFEYYRMXOJXZRJ-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Packaging

Unit quantity: 0.5 mL. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Caution

Other Notes

Sales restrictions may apply.

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2

Storage Class Code

10 - Combustible liquids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis

Enter Lot Number to search for Certificate of Analysis (COA).

Certificate of Origin

Enter Lot Number to search for Certificate of Origin (COO).

Joachim Erb et al.
The Journal of international medical research, 42(3), 750-764 (2014-05-02)
Levosimendan is an inotropic drug with organ-protective properties due to its activation of mitochondrial K(ATP) channels. This prospective, randomized, double-blind, placebo-controlled study investigated whether administration of levosimendan prior to cardiopulmonary bypass could reduce organ dysfunction and influence subsequent secondary endpoints.
D Schutte et al.
British journal of anaesthesia, 111(6), 967-970 (2013-07-26)
Asthma is a common disease in children and often develops early in life. This multicentre retrospective case series describe the use and effectiveness of sevoflurane inhalation therapy in a series of children with severe asthma in the paediatric intensive care
Norifumi Kuratani et al.
Anesthesiology, 109(2), 225-232 (2008-07-24)
Sevoflurane is a popular inhalational anesthetic for general anesthesia in children. The higher incidence of emergence agitation has been suspected after sevoflurane anesthesia as compared with halothane, whereas some controlled studies showed conflicting results. In this report, the authors performed
S Dahmani et al.
British journal of anaesthesia, 104(2), 216-223 (2010-01-06)
Emergence agitation (EA) in children is increased after sevoflurane anaesthesia. The efficacy of prophylactic treatment is controversial. The aim of this study was to provide a meta-analysis of the studies of the pharmacological prevention of EA in children. A comprehensive
Bjorn Heyse et al.
Anesthesiology, 120(6), 1390-1399 (2014-02-26)
The authors studied the interaction between sevoflurane and remifentanil on bispectral index (BIS), state entropy (SE), response entropy (RE), Composite Variability Index, and Surgical Pleth Index, by using a response surface methodology. The authors also studied the influence of stimulation

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service